|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2008-8-6
|
|
pubmed:abstractText |
Current recommendations that cancer patients receive a maximum cumulative dose of 900 mg/m(2) epirubicin are based on the risk of epirubicin-mediated cardiotoxicity and do not take into account the competing risk of death from cancer. Here, we identify risk factors for cardiotoxicity and overall mortality and determine the cumulative dose of epirubicin that yields a 5% risk for cardiotoxicity for cancer patients from different risk backgrounds.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
6
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1058-67
|
|
pubmed:meshHeading |
pubmed-meshheading:18664656-Adult,
pubmed-meshheading:18664656-Age Factors,
pubmed-meshheading:18664656-Aged,
pubmed-meshheading:18664656-Anthracyclines,
pubmed-meshheading:18664656-Antibiotics, Antineoplastic,
pubmed-meshheading:18664656-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18664656-Breast Neoplasms,
pubmed-meshheading:18664656-Chemotherapy, Adjuvant,
pubmed-meshheading:18664656-Cisplatin,
pubmed-meshheading:18664656-Cyclophosphamide,
pubmed-meshheading:18664656-Denmark,
pubmed-meshheading:18664656-Disease Susceptibility,
pubmed-meshheading:18664656-Drug Administration Schedule,
pubmed-meshheading:18664656-Epirubicin,
pubmed-meshheading:18664656-Female,
pubmed-meshheading:18664656-Fluorouracil,
pubmed-meshheading:18664656-Heart,
pubmed-meshheading:18664656-Heart Failure,
pubmed-meshheading:18664656-Humans,
pubmed-meshheading:18664656-Methotrexate,
pubmed-meshheading:18664656-Middle Aged,
pubmed-meshheading:18664656-Neoplasm Recurrence, Local,
pubmed-meshheading:18664656-Proportional Hazards Models,
pubmed-meshheading:18664656-Radiotherapy, Adjuvant,
pubmed-meshheading:18664656-Retrospective Studies,
pubmed-meshheading:18664656-Risk Factors,
pubmed-meshheading:18664656-Severity of Illness Index,
pubmed-meshheading:18664656-Tamoxifen,
pubmed-meshheading:18664656-Vindesine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
|
|
pubmed:affiliation |
Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. mary@heh.regionh.dk
|
|
pubmed:publicationType |
Journal Article
|
